HEALTH OF WOMAN. 2015.8(104):73–76 

Эффективность применения левофлоксацина в современной клинической практике 

Давыдова Ю. В., Лиманская А. Ю.

ГУ «Институт педиатрии, акушерства и гинекологии Национальной академии медицинских наук Украины», г. Киев 

В статье приведены данные об использовании левофлоксацина в современной клинической практике в условиях растущей резистентности патогенных микроорганизмов к большинству антибиотиков широкого спектра действия. Доказана эффективность левофлоксацина в лечении заболеваний разных органов и систем. 

Ключевые слова: левофлоксацин, фторхинолоны, резистентность к антибиотикам. 

Литература:

1. Ball P. 2000. Quinolone generations: natural history or natural selection? J. Antimicrob. Chemother. 46(1):17–24.

2. Scholar EM, Pratt WB. 2000. The antimicrobial drugs. 2nd ed. Oxford, New York: Oxford University Press.

3. Greenwood D, editor. 2001. Antimicrobial chemotherapy. 4th ed. Oxford, New York: Oxford University Press.

4. Березняков ИГ. 2004. Фторхинолоны: уникальный класс антибактериальных средств. Инфекции и антибиотики. Харьков, Константа:146–164.

5. Brown SD, Rybak MJ. 2004. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001–2002, as part of the PROTEKT US study. J. Antimicrob. Chemother. 54;1:i7–i15.

6. Jones RN, Sader HS, Beach ML. 2003. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18 569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY antimicrobial surveillance program (1997–2001). Int. J. Antimicrob. Agents. 22(6):551–6.

7. Pfaller MA, Sader HS, Frit-sche TR et al. 2006. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY antimicrobial surveillance program (1998–2004). Diagn. Microbiol. Infect. Dis. 56(1):63–8. http://dx.doi.org/10.1016/j.diagmicrobio.2006.02.009

8. Croom KF, Goa KL. 2003. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63(24):2769–802. http://dx.doi.org/10.2165/00003495-200363240-00008

9. Sahm DF, Benninger MS, Evangelista AT et al. 2007. Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001–2005). Otolaryngol. Head Neck Surg. 136(3):385–9.

10. Goff DA, Dowzicky MJ. 2007. Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J. Med. Microbiol. 56(9):1189–1195.

11. Licata L, Smith CE, Gold-shmidt RM et al. 1997. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumonia. Antimicrob. Agents Chemother. 41:950–955.

12. Shorr AF, Zadeikis N, Xiang JX et al. 2005. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ? 65 years with community-acquired pneumonia. Clin. Ther. 27(8):1251–1259.

13. Poole M, Anon J, Paglia M et al. 2006. A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. Otolaryngol. Head Neck Surg. 134(1):10–17.

14. Peterson J, Kaul S, Khashab M et al. 2008. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for 5 days with ciprofloxacin 400/500mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 71:17–22. http://dx.doi.org/10.1016/j.urology.2007.09.002; PMid:18242357

15. Anderson VR, Perry CM. 2008. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 68(4):535–565. http://dx.doi.org/10.2165/00003495-200868040-00011

16. Levaquin® (levofloxacin tablets, oral solution, injection): US prescribing information. – Raritan (NJ): Ortho-McNeil Pharmaceutical, Inc. 2008.

17. Bar-Oz B, Moretti M, Boskovic R et al. 2009, April. The safety of quinolones–A meta-analysis of pregnancy outcomes// European Journal of Obstetrics and Gynecology 143;2:75–78.

18. Sexually transmitted diseases, Treatment recommendations, CDC. 2010.

19. Mikamo H, Yamagishi Y, Takahashi K et al. 2011, Aug. Clinical study of levofloxacin 500 mg qd in the treatment of cervicitis and intrauterine infections caused by Chlamydia trachomatis. Jpn J Antibiot. 64(4):217–29.

20. Polachek H, Holcberg G, Sapir G et al. 2006, February. Transfer of Ciprofloxacin, Ofloxacin and Levofloxacin Across the Perfused Human Placenta In Vitro. Obstetrical and Gynecological Survey. 61;2:77–78.